Literature DB >> 31240465

Predictive value of monocytes and lymphocytes for short-term neutrophil changes in chemotherapy-induced severe neutropenia in solid tumors.

Buhong Zheng1, Zhiyu Huang1, Yunxia Huang1, Liang Hong1, Jinluan Li1, Junxin Wu2.   

Abstract

PURPOSE: To explore whether monocytes, lymphocytes, and platelets have a predictive value for short-term neutrophil changes in patients with severe neutropenia (SN) induced by chemotherapy.
METHODS: Complete blood counts (CBC) were collected from a total of 62 patients with chemotherapy-induced SN from December 2013 to March 2018. CBCs at intervals of 1 day, 2 days, 3 days, 4 days, and 5 days were recorded, and logistic regression analyses were performed to determine whether the monocyte percentage (MP), absolute monocyte count (AMC), lymphocyte percentage (LP), absolute lymphocyte count (ALC), or platelet count (PC) were correlated with short-term neutrophil changes. The areas under the receiver operating characteristic (ROC) curves (AUCs) were calculated for parameters with a P value < 0.05.
RESULTS: The MP was significantly correlated with changes in neutrophils for intervals of 1 to 5 days, while the LP was significantly correlated with changes in neutrophils for intervals of 2 to 5 days. A cutoff value of 6.5% for the MP yielded a sensitivity of 80%, a specificity of 88.6%, and an AUC of 0.908 for predicting an increase in neutrophils on the third day. A cutoff value of 14.75% for the LP yielded a sensitivity of 93.3%, a specificity of 70.3%, and an AUC of 0.812 for predicting an increase in neutrophils on the sixth day.
CONCLUSIONS: In chemotherapy-induced neutropenia patients, the MP is the best predictor of short-term neutrophil changes. Close monitoring and proper interpretation of the MP and LP are informative in managing chemotherapy-induced neutropenia.

Entities:  

Keywords:  Chemotherapy; Lymphocyte; Monocyte; Neutropenia; Platelet

Mesh:

Substances:

Year:  2019        PMID: 31240465     DOI: 10.1007/s00520-019-04946-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  24 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

Authors:  J de Naurois; I Novitzky-Basso; M J Gill; F Marti Marti; M H Cullen; F Roila
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

3.  Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.

Authors:  Derek Weycker; Xiaoyan Li; Spiros Tzivelekis; Mark Atwood; Jacob Garcia; Yanli Li; Maureen Reiner; Gary H Lyman
Journal:  Support Care Cancer       Date:  2016-10-12       Impact factor: 3.603

4.  Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.

Authors:  P Jenkins; J Scaife; S Freeman
Journal:  Ann Oncol       Date:  2011-11-02       Impact factor: 32.976

5.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

6.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

Review 7.  Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.

Authors:  Gary H Lyman; Esteban Abella; Ruth Pettengell
Journal:  Crit Rev Oncol Hematol       Date:  2013-12-12       Impact factor: 6.312

8.  Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.

Authors:  A Bosly; D Bron; A Van Hoof; R De Bock; Z Berneman; A Ferrant; L Kaufman; M Dauwe; G Verhoef
Journal:  Ann Hematol       Date:  2007-10-20       Impact factor: 3.673

Review 9.  The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.

Authors:  Jean Klastersky; Marianne Paesmans
Journal:  Support Care Cancer       Date:  2013-02-27       Impact factor: 3.603

10.  Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.

Authors:  Chul Won Choi; Hwa Jung Sung; Kyong Hwa Park; So Young Yoon; Seok Jin Kim; Sang Cheul Oh; Jae Hong Seo; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim
Journal:  Am J Hematol       Date:  2003-08       Impact factor: 10.047

View more
  2 in total

1.  Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor.

Authors:  Osama Alshari; Yazan O Al Zu'bi; Ahmed H Al Sharie; Farouk H Wafai; Abdelwahab J Aleshawi; Farah H Atawneh; Hasan A Obeidat; Majd N Daoud; Mohammad Z Khrais; Dima Albals; Faize Tubaishat
Journal:  Ther Clin Risk Manag       Date:  2021-09-07       Impact factor: 2.423

2.  Stimulating the Hematopoietic Effect of Simulated Digestive Product of Fucoidan from Sargassum fusiforme on Cyclophosphamide-Induced Hematopoietic Damage in Mice and Its Protective Mechanisms Based on Serum Lipidomics.

Authors:  Wei-Ping Ma; Shi-Ning Yin; Jia-Peng Chen; Xi-Cheng Geng; Ming-Fei Liu; Hai-Hua Li; Ming Liu; Hong-Bing Liu
Journal:  Mar Drugs       Date:  2022-03-09       Impact factor: 5.118

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.